ClinicalTrials.gg
RecruitingNCT03992729Updated Jan 21, 2026

Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab

An observational study in Pregnancy Related, sponsored by Sun Pharmaceutical Industries Limited. Recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Sun Pharmaceutical Industries Limited · Observational

How we know

From the registry’s dates

  • Started Aug 2019; still recruiting 7 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Sex
Female
01

Study summary

This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to tildrakizumab during pregnancy to treat an approved indication.

The pregnancy registry cohort study will be conducted by the Organization of Teratology Information Specialists (OTIS), which is a network of university and health department based information centers serving pregnant women and healthcare providers throughout North America. These services provide a basis for collaborative research such as this Registry.

These Services located throughout the United States (US) and Canada will serve as a source of referrals not only for tildrakizumab-exposed pregnancies but also for similarly ascertained disease-matched comparison pregnant women who have not used tildrakizumab in pregnancy.

The target follow-up period will be until end of pregnancy and 1 year of age for live born infants.

02

Conditions studied

  • Pregnancy Related
03

In context

Lead sponsor

Sun Pharmaceutical Industries Limited is the lead sponsor of 60 studies on the registry; 5 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 22 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant women diagnosed with tildrakizumab-approved indication with and without tildrakizumab

Eligibility criteria

Cohort 1: Tildrakizumab-Exposed Cohort

  1. Pregnant women
  2. Exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period up to and including the end of pregnancy
  3. Agree to the conditions and requirements of the study including the interview schedule, and release of medical records

Cohort 2: Disease-Matched Comparison Cohort

  1. Pregnant women
  2. Diagnosed with a tildrakizumab-approved indication; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible
  3. No exposure to tildrakizumab at any time in the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy
  4. Agree to the conditions and requirements of the study including the interview schedule, and release of medical records

Exclusion criteria:

Cohort 1: Tildrakizumab-Exposed Cohort:

  1. Women who have first contact with the project after prenatal diagnosis of any major structural defect
  2. Women who have enrolled in the tildrakizumab cohort study with a previous pregnancy (women may only enroll once in the Tildrakizumab Pregnancy Study)
  3. Women who have used tildrakizumab for an indication other than a currently approved indication
  4. Retrospective enrollment after the outcome of pregnancy is known

Cohort 2: Disease-Matched Comparison Cohort

  1. Women who have first contact with the project after prenatal diagnosis of any major structural defect
  2. Exposure to tildrakizumab anytime during the current pregnancy
  3. Women who have enrolled in the tildrakizumab cohort study with a previous pregnancy (women may only enroll once in the Tildrakizumab Pregnancy Study)
  4. Retrospective enrollment after the outcome of pregnancy is known
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
20 Months
Patient registry
Yes

Groups and cohorts

  • Tildrakizumab-Exposed Cohort

    Exposure to tildrakizumab for the treatment of an approved indication

    Drug: Pregnant women exposed to tildrakizumab

  • Disease-Matched Comparison Cohort

    No exposure to tildrakizumab at any time in the current pregnancy

    Drug: Pregnant women not exposed to tildrakizumab

Interventions

  • DrugPregnant women exposed to tildrakizumab

    Subjects exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy

  • DrugPregnant women not exposed to tildrakizumab

    Subjects diagnosed with a tildrakizumab-approved indication; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible, and Subjects with no exposure to tildrakizumab at any time in the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy

06

What researchers measure

Primary outcomes

  1. Major structural defects in children

    defined and classified using the US Centers for Disease Control and Prevention (CDC) coding manual that is used for the Metropolitan Atlanta Congenital Defects Program (MACDP) classification of major structural defects

    Time frame: Up to 1 year of age

Secondary outcomes

  1. Spontaneous abortion/miscarriage

    defined as non-deliberate fetal death that occurs prior to 20.0 weeks post-last menstrual period

    Time frame: 20 weeks post-last menstrual period

  2. Stillbirth

    defined as non-deliberate fetal death anytime in gestation at or after 20.0 weeks post-last menstrual period

    Time frame: from 20 weeks post-last menstrual period to end of pregnancy

  3. Elective termination/abortion

    defined as deliberate discontinuation of pregnancy through medication or surgical procedures

    Time frame: At the end of pregnancy or through 9 month pregnancy period

  4. neonatal/infant death

    defined as any death in a live born infant during the first 6 months of age

    Time frame: 6 months of age

  5. Small for gestational age

    defined as birth size (weight, length, or head circumference) less than or equal to the 10th centile for sex and gestational age using standard pediatric CDC growth curves for full term or preterm infants

    Time frame: at birth

  6. Postnatal growth deficiency

    defined as postnatal size (weight, length or head circumference) less than or equal to the 10th centile for sex and age using standard pediatric growth curves and adjusted for postnatal age for premature infants if the postnatal measurement is obtained at less than 1 year of age

    Time frame: Up to 1 year of age

  7. Malignancies in live born children

    defined as any malignancy reported in an infant within the first year of life

    Time frame: Up to 1 year of age

  8. Hospitalization in live born children

    defined as any hospitalization of the infant within the first year of life after discharge following delivery

    Time frame: Up to 1 year of age

  9. Postnatal serious or opportunistic infection in live born children

    defined as any infection resulting in hospitalization, X-ray proven pneumonia, neonatal sepsis, meningitis, osteomyelitis, bacteremia, septic arthritis, abscess, mycobacteria infections, invasive fungal infection including histoplasmosis, coccidiomycosis, candidiasis, aspergillosis, and blastomycosis, pneumocystis jirovecii infection, systemic cytomegalovirus, herpes zoster and herpes simplex infection, listeria infections, and Legionella infection.

    Time frame: Up to 1 year

07

Study locations

1 of 1 sites recruiting
  • Christina Chambers
    San Diego, California 92093, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2019 (actual). Primary completion is estimated for Jul 2028, 107 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2019
First posted
Jun 20, 2019
StartActual
Aug 29, 2019
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03992729
Responsible party
Sponsor
First posted
Jun 20, 2019
Start date
Aug 29, 2019
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Jan 21, 2026

Study contacts

Head, Clinical Development
Contact
Clinical.Trial@sunpharma.com
91 2266455645 ext. 5689

Oversight

FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion